S

Santhera Pharmaceuticals Holding AG
SIX:SANN

Watchlist Manager
Santhera Pharmaceuticals Holding AG
SIX:SANN
Watchlist
Price: 12.88 CHF -0.16% Market Closed
Market Cap: 174m CHF

Intrinsic Value

The intrinsic value of one SANN stock under the Base Case scenario is 42.73 CHF. Compared to the current market price of 12.88 CHF, Santhera Pharmaceuticals Holding AG is Undervalued by 70%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

SANN Intrinsic Value
42.73 CHF
Undervaluation 70%
Intrinsic Value
Price
S
Worst Case
Base Case
Best Case

Valuation History
Santhera Pharmaceuticals Holding AG

What is Valuation History?
Ask AI Assistant
What other research platforms think about SANN?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is SANN valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Santhera Pharmaceuticals Holding AG.

Explain Valuation
Compare SANN to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about SANN?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Santhera Pharmaceuticals Holding AG

Current Assets 33.6m
Cash & Short-Term Investments 16.5m
Receivables 10.4m
Other Current Assets 6.7m
Non-Current Assets 74.6m
Long-Term Investments 342k
PP&E 2.8m
Intangibles 71.5m
Current Liabilities 53.1m
Accounts Payable 14.9m
Accrued Liabilities 10.2m
Other Current Liabilities 27.9m
Non-Current Liabilities 7.1m
Long-Term Debt 2.4m
Other Non-Current Liabilities 4.7m
Efficiency

Free Cash Flow Analysis
Santhera Pharmaceuticals Holding AG

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Santhera Pharmaceuticals Holding AG

Revenue
49m CHF
Cost of Revenue
-42.4m CHF
Gross Profit
6.6m CHF
Operating Expenses
-57.4m CHF
Operating Income
-50.8m CHF
Other Expenses
-14.7m CHF
Net Income
-65.5m CHF
Fundamental Scores

SANN Profitability Score
Profitability Due Diligence

Santhera Pharmaceuticals Holding AG's profitability score is 33/100. The higher the profitability score, the more profitable the company is.

33/100
Profitability
Score

Santhera Pharmaceuticals Holding AG's profitability score is 33/100. The higher the profitability score, the more profitable the company is.

SANN Solvency Score
Solvency Due Diligence

Santhera Pharmaceuticals Holding AG's solvency score is 41/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Low D/E
Long-Term Solvency
Short-Term Solvency
41/100
Solvency
Score

Santhera Pharmaceuticals Holding AG's solvency score is 41/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

SANN Price Targets Summary
Santhera Pharmaceuticals Holding AG

Wall Street analysts forecast SANN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SANN is 30.6 CHF with a low forecast of 30.3 CHF and a high forecast of 31.5 CHF.

Lowest
Price Target
30.3 CHF
135% Upside
Average
Price Target
30.6 CHF
138% Upside
Highest
Price Target
31.5 CHF
145% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Santhera Pharmaceuticals Holding AG
does not pay dividends
Shareholder Yield

Current shareholder yield for SANN is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y
What is the Intrinsic Value of one SANN stock?

The intrinsic value of one SANN stock under the Base Case scenario is 42.73 CHF.

Is SANN stock undervalued or overvalued?

Compared to the current market price of 12.88 CHF, Santhera Pharmaceuticals Holding AG is Undervalued by 70%.

Back to Top